• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

AI drug development partnership between GlaxoSmithKline, Exscientia yields first drug candidate

Share:

April 9, 2019

The in vivo molecule was discovered under a two-year-old partnership between the two companies to discovery drugs using artificial intelligence. It will be developed for COPD.

A partnership between a large British drugmaker and a startup that discovers drugs using artificial intelligence has borne fruit.

Oxford, UK-based Exscientia said Wednesday that it had delivered the first drug candidate to be found using its AI collaboration with GlaxoSmithKline, a potential therapy for chronic obstructive pulmonary disorder, or COPD.

The company said it was developed through application of its Centaur Chemist AI-driven automated drug discovery platform. The system was able to find the molecule with fewer compounds synthesized in comparison with drugs discovered through conventional means. The partnership between GSK and Exscientia dates back to July 2017.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

“Our AI platform and approach have advanced significantly over the past few years and have been constantly refined and optimized through real-world projects for our pharma partners,” said Andy Bell, Exscientia’s chief research officer, in a statement. “With the productivity improvements we are now seeing, we believe that our Centaur Chemist approach is proving itself to be the industry’s leading AI drug-discovery platform by achieving far superior results to what conventional discovery techniques have historically delivered.”

The exploration of AI and machine learning in drug discovery and development has drawn considerable interest from drugmakers in recent years, though it remains in its infancy, and it could be some time before integration of the two fields becomes fully mainstreamed.

Still, a number of companies large and small have been exploring the idea of AI/ML in developing new drugs, in particular because of its potential to speed along the process of drug development and even find new druggable targets that conventional methods would miss. For example, AI/ML combined with cryo-electron microscopy can allow researchers to correctly infer three-dimensional structures of molecules and then map them at the atomic level in ways not possible using traditional X-ray crystallography.

In January, the large contract research organization Charles River Labs and Atomwise announced a partnership to provide AI services in drug discovery. A partnership announced last June between Swiss drugmaker Novartis and chipmaker Intel is using AI to cut the amount of time required to analyze microscopic images from 11 hours to 31 minutes. Also in July, Salt Lake City-based Recursion Pharmaceuticals got the go-ahead from the Food and Drug Administration to start a Phase I study of REC-994, a drug candidate discovered through machine learning that it is developing for the genetic disease cerebral cavernous malformation. However, there has not been a public update on that program since.

Date: April 09, 2019

Source: MedCityNews

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • How health insurance companies use AI to make consumers healthierHow health insurance companies use AI to make consumers healthier
  • CRH Medical Corporation Announces Completion of Majority Acquisition of Triad Sedation Associates, Llc
  • InsureTech Chatbot Platform Sensely Raises $15M to Modernize Member ExperienceInsureTech Chatbot Platform Sensely Raises $15M to Modernize Member Experience
  • Phynd Announces Partnership with MedTouch to Provide Best-in-Class Digital Front Door for Patient-Care AccessPhynd Announces Partnership with MedTouch to Provide Best-in-Class Digital Front Door for Patient-Care Access
  • Oncoshot Partners with Mydoc to Offer Second Opinion Advice for Cancer PatientsOncoshot Partners with Mydoc to Offer Second Opinion Advice for Cancer Patients
  • Ultromics and Mayo Clinic Partner up for Ai Diagnosis of Heart FailureUltromics and Mayo Clinic Partner up for Ai Diagnosis of Heart Failure
  • Sinopharm buys 60 pct device distributor for $765 mlnSinopharm buys 60 pct device distributor for $765 mln
  • Insights on Precision Oncology Developments in Japan and BeyondInsights on Precision Oncology Developments in Japan and Beyond

Trending This Week

  • Pharmaceutical Logistics Market 2020 Size, Growth Rate, Share, Statistics, Trends, COVID-19 Impact, Key PlayerS
  • Hepcidin Market Insights, Trends, Size, Share and Forecast 2020 – 2027
  • COVID-19 Drug API Market is set for Lucrative Growth
  • Vitamins and Minerals Market Trends, Insights and Forecast 2020 – 2027
  • Global COVID-19 Treatment Industry Top-Vendor And Industry Insights By End-User Segments Till 2027
  • Revive Therapeutics Acquires Unique Psilocybin Assets

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications